Pfizer’s state-of-the-art facility will foster
the continued development of the biotechnology industry in China,
further supporting National healthcare reforms
Pfizer Inc. today announced that it will invest approximately
USD$350 million in the development of a state-of-the-art Global
Biotechnology Center at a ground-breaking ceremony in the Hangzhou
Economic Development Area (HEDA) in China.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160627006468/en/
AERIAL VIEW NORTH EAST (Photo: Business
Wire)
This innovative facility will be Pfizer’s third biotechnology
center globally and the first in Asia. It will ensure the local
production of high-quality, affordable biosimilar medicines that
will benefit patients both in China and throughout the world. The
establishment of the Pfizer Global Biotechnology Center also
represents further investment in R&D and clinical research
across China, which will further contribute to China’s growing
biopharmaceutical industry and economy.
This Global Biotechnology Center will include an advanced
modular facility by GE Healthcare (NYSE:GE), based on flexible
single-use bio-manufacturing technology that meets strict
international standards for quality, safety and efficiency, as well
as accelerated speed of construction and superior environmental
standards.
This Center is expected to be completed in 2018. Pfizer will
work closely with Chinese regulators to bring the biosimilar
products produced at the Pfizer Global Biotechnology Center in
Hangzhou to market as soon as possible.
“We believe that the Pfizer Global Biotechnology Center in
Hangzhou will help support China’s aim to increase the complexity
and value of its manufacturing sector by 2025, and contribute to
building a truly innovative and vibrant biopharmaceutical
industry,” said John Young, Group President, Pfizer Essential
Health.
“We are encouraged by a series of important reforms introduced
by Chinese government that will further stimulate the industry to
meet emerging health challenges, such as the rising incidence of
non-communicable diseases and an aging population; as well as
attract both domestic and foreign investment in healthcare and
R&D.”
The Pfizer Global Biotechnology Center aims to support China’s
healthcare reforms, assist the Chinese government in its continuing
efforts to update the local industry in this sector, and provide
world-class biological medicines for patients in China and the
world. The facility will house Pfizer China’s Biosimilars and
Biologics Quality, Technical Service, Logistics and Engineering
divisions, in addition to commercial manufacturing, and will also
serve as a process development and clinical supply site.
This center will create more than 150 job opportunities and
establish local biotechnology expertise that will help strengthen
and promote innovation as well as modernize China’s
biopharmaceutical industry.
“We plan on building on Pfizer’s 30-year history in China by
applying our Global expertise in manufacturing excellence and
world-class capabilities to bring high-quality biosimilars to
market,” said Tony Maddaluna, President of Pfizer Global Supply.
“The local production of high-quality, affordable biosimilar
medicines will have the potential to significantly improve the
lives of patients not only in China but across the world.”
The new center will feature GE’s single-use technology in a
KUBioTM modular facility, which increases speed-to-market and
manufacturing flexibility at costs of between 25 and 50 percent of
equivalent traditional facilities in a build time that can be just
18 months as opposed to the usual three years. Carbon dioxide
emissions, water and energy usage can also be reduced by 75
percent.
“As governments and companies the world over strive to give
patients access to a new class of life-changing biological
medicines, GE’s KUBio modular factories allow biopharmaceutical
companies to get their products to market quickly so they can
respond rapidly to local healthcare needs. KUBio’s modular
construction and single-use technologies, coupled with GE’s deep
expertise in bioprocessing design, enable speed and increased
productivity at global GMP standards wherever they are needed,”
said Kieran Murphy, CEO & President, GE Healthcare Life
Sciences.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of healthcare
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer healthcare
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. For more information, please visit us at
www.pfizer.com. In addition, to learn more, follow us on Twitter at
@Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on
Facebook at Facebook.com/Pfizer.
Disclosure Notice: The information contained in this release is
as of June 27, 2016. Pfizer assumes no obligation to update
forward-looking statements contained in this release as the result
of new information or future events or developments. This release
contains forward-looking information about Pfizer’s investment in
the development of a Global Biotechnology Center in
China, including its potential benefits and the
anticipated timing of completion, that involves substantial risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
Risks and uncertainties include, among other things, risks related
to the ability to realize the anticipated benefits of the Global
Biotechnology Center and the ability to complete construction in
the anticipated timeframe or at all; other business effects,
including the effects of industry, market, economic, political or
regulatory conditions; and competitive developments. A further
description of risks and uncertainties can be found in Pfizer’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2015 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as
in its subsequent reports on Form 8-K, all of which are filed with
the U.S. Securities and Exchange Commission and available at
www.sec.gov(link is external).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160627006468/en/
Pfizer Media:Kim Bencker, +1 610 329
1340Kim.bencker@pfizer.comorTrupti Deepak Wagh, +65
91873247Trupti.wagh@pfizer.comorChinaOuyang Jie, (86-10) 8516
7345Jie.ouyang@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024